Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The company's product candidates also include AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Its AFM21 product also binds CD3, directing T-cells to destroy tumor cells that carry EGFRvIII. Affimed N.V. has license agreements with Amphivena Therapeutics, Inc. and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and clinical research collaboration with Merck & Co Inc. It also has a strategic clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate Affimed's TandAb technology in combination with MD Anderson's natural killer cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
http://www.priceseries.com/trade/AFMD-Affimed-NV-stock-gains-74-percent-a-Trade-Record-by-priceSeries-2020110920201218.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments